3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
4
CNS
3
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
lutetium Lu 177 dotatate
14
Nivolumab
12
Magnetic Resonance Spectroscopy
11
pembrolizumab
10
Specimen Handling
10
Ipilimumab
9
cabozantinib
8
trametinib
6
lenvatinib
6
Temozolomide
6
dabrafenib
4
atezolizumab
4
Lutetium-177
4
Immunoglobulin G
4
Everolimus
4
Disulfides
4
CTLA-4 Antigen
4
selpercatinib
3
Octreotide
3
Cisplatin
3
Carboplatin
3
Capecitabine
3
Bevacizumab
3
entrectinib
2
copper dotatate CU-64
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Vemurafenib
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
entrectinib
×
Endocrine
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA